May 2003
Volume 44, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2003
Blood Pressure Effects on Bremazocine IOP Response; Outflow Facility in Cynomolgus Monkeys
Author Affiliations & Notes
  • C.A. Rasmussen
    Ophthalmology & Visual Science, University of Wisconsin, Madison, WI, United States
  • B.T. Gabelt
    Ophthalmology & Visual Science, University of Wisconsin, Madison, WI, United States
  • K.R. Russell
    Pharmacology & Toxicology, Morehouse School of Medicine, Atlanta, GA, United States
  • B. Tian
    Pharmacology & Toxicology, Morehouse School of Medicine, Atlanta, GA, United States
  • P.L. Kaufman
    Pharmacology & Toxicology, Morehouse School of Medicine, Atlanta, GA, United States
  • Footnotes
    Commercial Relationships  C.A. Rasmussen, None; B.T. Gabelt, None; K.R. Russell, None; B. Tian, None; P.L. Kaufman, None.
  • Footnotes
    Support  NIH Grant EY02698 and RPB
Investigative Ophthalmology & Visual Science May 2003, Vol.44, 3436. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      C.A. Rasmussen, B.T. Gabelt, K.R. Russell, B. Tian, P.L. Kaufman; Blood Pressure Effects on Bremazocine IOP Response; Outflow Facility in Cynomolgus Monkeys . Invest. Ophthalmol. Vis. Sci. 2003;44(13):3436.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To further characterize the ocular hypotensive mechanism of bremazocine HCl (BRE), a kappa opioid receptor agonist, shown to lower intraocular pressure (IOP), and decrease aqueous humor formation (AHF) in monkeys and rabbits. Methods: Mean arterial pressure (MAP), calculated as 2/3 diastolic + 1/3 systolic blood pressure, was recorded, via cuff or arterial line, at 15 min intervals, and IOP (Goldmann tonometer) was recorded at 30 min intervals for 4-6 hours, in 5 ketamine-anesthetized normotensive cynomolgus monkeys after topical administration of a single dose of 10µg or 100µg BRE in 2 x 5 µl drops to one eye, vehicle to opposite eyes. In separate experiments, angiotensin II (ATII), in a 0.303µg/ml solution, was infused at a rate between 200µl-600µl min to maintain MAP after 100µg BRE administration. Outflow facility (OF) was determined by two-level constant pressure perfusion of the anterior chamber (AC) with Bárány’s solution, followed by AC exchanges with 2 or 3 doses of BRE, ranging from 0.01µg/ml to 100µg/ml in 8 monkeys under pentobarbital anesthesia. Results: BRE caused a dose-related decrease in MAP. The 10µg dose significantly decreased MAP compared to same-day pretreatment baseline (BL) at hrs 0.5,1.0 and 2.0 (p<0.05; n=5), with a maximum decrease of 23% at 0.5 hrs. MAP returned to BL at 3 hrs. The 100µg dose significantly reduced MAP from hrs 0.5 –2 after treatment (p<0.05; n=5) with a maximum decrease of 39% at 1 hr. MAP returned to BL at 6 hrs. Maintaining MAP at near BL levels with ATII after topical administration of 100µg BRE eliminated the decrease in IOP. ATII alone, infused at 200µl-600µl min, caused an 18-29% (mean 24±0.02 n=5) increase in MAP over 4 hours, and a 6-11% (mean 9±0.01 n=5) increase in IOP. OF measurements to date showed that BRE insignificantly decreased OF. No toxicity was observed at any dose by slit lamp biomicroscopy. Conclusions: The IOP lowering effect of topical BRE, in monkeys, is likely due to the significant drop in MAP which is probably also responsible for the decrease in AHF reported previously. BRE does not appear to alter OF in monkeys.

Keywords: intraocular pressure • outflow: trabecular meshwork • aqueous 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×